Management of drug interactions in patients with HIV

被引:34
作者
Tseng, ALI
Foisy, MM
机构
[1] UNIV TORONTO, FAC PHARM, TORONTO, ON, CANADA
[2] UNIV TORONTO, WELLESLEY HOSP, TORONTO, ON M4Y 1J3, CANADA
关键词
human immunodeficiency virus; drug interactions;
D O I
10.1177/106002809703100915
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: To provide a compilation of relevant information on drug interactions to assist healthcare practitioners in managing complex HIV-related pharmacotherapy. DATA SOURCES: Information was retrieved via a MEDLINE search (January 1966-December 1996) using MeSH headings ''human immunodeficiency virus,'' ''drug interactions,'' and names of medications commonly prescribed for the management of HIV infection and related opportunistic infections. Abstracts of international and national conferences, review articles, textbooks, and references of all articles were also searched. STUDY SELECTION AND DATA EXTRACTIONS: All literature on pharmacokinetic or pharmacodynamic interactions was considered for inclusion. Pertinent information, as assessed by the authors, was selected and summarized for discussion. DATA SYNTHESIS: Drug disposition and/or pharmacologic effect may be affected either by HIV-related physiologic changes or by the presence of concomitant drug therapy. Modifications in drug selection, dosage, dosing regimen, or route of administration may be needed to avoid or manage drug-disease, drug-drug, or drug-food interactions. Management options may depend on the mechanism and the clinical significance of the interaction, the availability of therapeutic alternatives, patient convenience, and cost restrictions. In the absence of specific data, consideration of pharmacokinetic and pharmacodynamic characteristics to assist practitioners in predicting the likelihood of possible interactions was included. RESULTS: A comprehensive table of clinically significant drug interactions is provided. Drug interaction principles and practical management strategies are also discussed. CONCLUSIONS: The potential for drug interactions is extremely common, given the increasing complexity of managing patients infected with HIV, To avoid compromising therapeutic efficacy or increasing drug toxicity, practitioners need to be aware of potential interactions and are encouraged to use a systematic approach when managing patient drug therapy.
引用
收藏
页码:1040 / 1058
页数:19
相关论文
共 159 条
[81]  
KUCERS A, 1987, USE ANTIBIOTICS COMP, P936
[82]   GASTROPATHY AND KETOCONAZOLE MALABSORPTION IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) [J].
LAKEBAKAAR, G ;
TOM, W ;
LAKEBAKAAR, D ;
GUPTA, N ;
BEIDAS, S ;
ELSAKR, M ;
STRAUS, E .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (06) :471-473
[83]  
LAMSON M, 1997, 4 NAT C RETR OPP INF
[84]  
LANGE D, 1995, 35 INT C ANT AG CHEM
[85]  
LAVRIJSEN K, 1995, PHARM C BETH
[86]  
LAZAR JD, 1990, REV INFECT DIS, V12, pS327
[87]   Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine [J].
Lee, BL ;
Tauber, MG ;
Sadler, B ;
Goldstein, D ;
Chambers, HF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :14-21
[88]   DAPSONE, TRIMETHOPRIM, AND SULFAMETHOXAZOLE PLASMA-LEVELS DURING TREATMENT OF PNEUMOCYSTIS PNEUMONIA IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) - EVIDENCE OF DRUG-INTERACTIONS [J].
LEE, BL ;
MEDINA, I ;
BENOWITZ, NL ;
JACOB, P ;
WOFSY, CB ;
MILLS, J .
ANNALS OF INTERNAL MEDICINE, 1989, 110 (08) :606-611
[89]   INTERACTIONS AND TOXICITIES OF DRUGS USED IN PATIENTS WITH AIDS [J].
LEE, BL ;
SAFRIN, S .
CLINICAL INFECTIOUS DISEASES, 1992, 14 (03) :773-779
[90]  
LEE BL, 1995, 35 INT C ANT AG CHEM